Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
Plos One|April 20, 2016
Weight and Glucose Reduction Observed with a Combination of Nutritional Agents in Rodent Models Does Not Translate to Humans in a Randomized Clinical Trial with Healthy Volunteers and Subjects with Type 2 DiabetesRebecca J Hodge, Mark A Paulik, Ann Walker, et al.Journal of Medicinal Chemistry|September 3, 2004
N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacyFrancis X Tavares, Joyce A Boucheron, Scott H Dickerson, et al.Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel GSK-3 inhibitors with improved cellular activityAndrew J Peat, Dulce Garrido, Joyce A Boucheron, et al.Bioorganic & Medicinal Chemistry Letters|February 8, 2006
Synthesis and evaluation of novel heterocyclic inhibitors of GSK-3Terrence L Smalley, Andrew J Peat, Joyce A Boucheron, et al.Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Novel pyrazolopyrimidine derivatives as GSK-3 inhibitorsAndrew J Peat, Joyce A Boucheron, Scott H Dickerson, et al.The Journal of Pharmacology and Experimental Therapeutics|June 30, 2011
Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonistDiane M Ignar, Aaron S Goetz, Kimberly Nichols Noble, et al.Bioorganic & Medicinal Chemistry Letters|June 17, 2008
Amino acid anthranilamide derivatives as a new class of glycogen phosphorylase inhibitorsKaren A Evans, Yue H Li, Frank T Coppo, et al.Bioorganic & Medicinal Chemistry Letters|January 14, 2009
Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacyStephen A Thomson, Pierette Banker, D Mark Bickett, et al.Pageof 1